Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 20Breast Neoplasms 7Salivary Gland Neoplasms 1Prostate Adenocarcinoma 1Neoplasms 1Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel 1Drug-Related Side Effects and Adverse Reactions 1Bulbo-Spinal Atrophy, X-Linked 1Breast Cancer Invasive Nos 1Adenocarcinoma 1

Interventions

bicalutamide 4pembrolizumab 1nilutamide 1exemestane 1darolutamide 1cabazitaxel 1apalutamide 1abemaciclib 1Vorinostat 1Triptorelin Pamoate 1Tamoxifen 1Letrozole 1Histamine H2 Antagonists 1Histamine Antagonists 1Goserelin 1Doxorubicin 1Dasatinib 1Cisplatin 1CP protocol 1Aromatase Inhibitors 1Antiemetics 1Anastrozole 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bulbo-Spinal Atrophy, X-Linked × Triptorelin Pamoate × Clear all
NCT01969578 2024-11-05

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
149 enrolled
Head & Neck

Adenocarcinoma, Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡